E-DRUG Archives (by date)

• Thread Index

February 28, 2006
• [e-drug] ARV adherence in resource-poor settings (2)
  • From: "K.F.Steinhausen" <kfsteinhausen@gmx.net>
• [e-drug] How to analyze drug promotional material? (2)
  • From: "Joel Lexchin (York)" <jlexchin@yorku.ca>
• [e-drug] Counterfeit medicines: the silent epidemic (4)
  • From: "bhava narayana" <editorptn@gmail.com>
• [e-drug] ARV adherence in resource-poor settings
  • From: "Atieno Ojoo" <atisojoo@yahoo.co.uk>
• [e-drug] Counterfeit medicines: the silent epidemic (3)
  • From: "E-Drug" <e-drug@healthnet.org>
• [e-drug] Counterfeit medicines: the silent epidemic (2)
  • From: "Jorg Schaaber" <jschaaber@bukopharma.de>
• [e-drug] IDA Solutions seeks pharmaceutical supply management consultant
  • From: "Heather Houlihan" <hhoulihan@idasolutions.org>
• [e-drug] How to analyze drug promotional material?
  • From: "Mian Imran Masood" <drimranmasood@gmail.com>
• [e-drug] Australian Medicines Conference scholarship for Asia Pacific
  • From: "Lynn Weekes" <lweekes@nps.org.au>
February 27, 2006
• [e-drug] Mark-up percentages for Drug Revolving Funds (11)
  • From: "Gamal Khalafalla Mohammed" <gamalkh@hotmail.com>
February 26, 2006
• [e-drug] HIV/AIDS management course, Tanzania, 15-19 May 2006
  • From: "Dr. O.M.S. Minzi" <ominzi@muchs.ac.tz>
February 24, 2006
• [e-drug] Mark-up percentages for Drug Revolving Funds (10)
  • From: "BONFACE FUNDAFUNDA" <bcfunda@hotmail.com>
February 23, 2006
• [e-drug] Counterfeit Medicines: A Public Health Policy Failure
  • From: "Zaheer UD Din Babar" <zaheerb@ucsi.edu.my>
• [e-drug] Status of Cipla's imatinib in Guatemala?
  • From: "Joana Ramos" <joaninha@comcast.net>
February 22, 2006
• [e-drug] Paying for expensive cancer drugs
  • From: "Joel Lexchin" <joel.lexchin@utoronto.ca>
• [e-drug] Mark-up percentages for Drug Revolving Funds (9)
  • From: "Maggie Huff-Rousselle" <mhuffrousselle@ssds.net>
• [e-drug] Artemisin Combination Therapy (ACT) How Safe and Gentle?
  • From: "fola tayo" <folatayo2001@yahoo.com>
• [e-drug] Counterfeit medicines: the silent epidemic
  • From: "E-Drug" <e-drug@healthnet.org>
• [e-drug] Mark-up percentages for Drug Revolving Funds (8)
  • From: "sewuese batur-laha" <praisepharm@yahoo.com>
• [e-drug] Mark-up percentages for Drug Revolving Funds (7)
  • From: "MAVERE TUKAI" <mtukai@yahoo.com>
• [e-drug] Zinc for infantile diarrhea (5)
  • From: "Murtada Sesay" <msesay@unicef.org>
• [e-drug] Mark-up percentages for Drug Revolving Funds (6)
  • From: "Richard Laing" <laingr@who.int>
• [e-drug] Zinc for infantile diarrhea (4)
  • From: "Sri" <sri.chari@gmail.com>
• [e-drug] Mark-up percentages for Drug Revolving Funds (5)
  • From: "Michael Keizer" <mkeizer@unicef.org>
• [e-drug] Mark-up percentages for Drug Revolving Funds (4)
  • From: "Evans Sagwa" <esagwa@yahoo.com>
February 21, 2006
• [e-drug] ARV Program Management course 7-18 August Boston
  • From: "Sarah Petty" <spetty@bu.edu>
• [e-drug] Mark-up percentages for Drug Revolving Funds (3)
  • From: "Raja Rao" <raja_rao@jsi.com>
• [e-drug] ARV DSM Training 5-18 March South Africa
  • From: "Melinda Wannenburg" <Melinda@aa4a.co.za>
• [e-drug] Zinc for infantile diarrhea (3)
  • From: "Hans V. Hogerzeil" <hogerzeilh@who.int>
• [e-drug] Mark-up percentages for Drug Revolving Funds (2)
  • From: "Libby Levison" <libby@theplateau.com>
• [e-drug] prescribing and dispensing indicators in public health facilities
  • From: "Sosola" <sosola@malawi.net>
February 20, 2006
• [e-drug] Dilemma of missing essential drugs in Pakistan
  • From: "Huma Rasheed" <huma_rasheed@hotmail.com>
• [e-drug] Mark-up percentages for Drug Revolving Funds
  • From: "Salisu Hashim" <pharmmshashim@yahoo.com>
• [e-drug] Pediatric Drug Info source
  • From: "Klara Tisocki" <ktisocki@yahoo.ie>
• [e-drug] How to deal with H5N1 avian influenza outbreaks? (2)
  • From: "Klara Tisocki" <ktisocki@yahoo.ie>
• [e-drug] RFI: JuneLab PsoriaClear and Eczemate? (4)
  • From: "Drug Information " <druginformation@moh.gov.sc>
February 18, 2006
• [e-drug] WHO Board adopts decision on trade and health
  • From: "E-Drug" <e-drug@healthnet.org>
• [e-drug] BMJ on melatonin and sleep disorders
  • From: "E-Drug" <e-drug@healthnet.org>
February 17, 2006
• [e-drug] Seeking feedback on The WHO Model Formulary
  • From: "Suzanne Hill" <HillS@who.int>
• [e-drug] DFID factsheet on Access to (Essential) Medicines
  • From: "Wilbert Bannenberg" <wjb@wxs.nl>
February 16, 2006
• [e-drug] RFI: JuneLab PsoriaClear and Eczemate? (3)
  • From: "Andy Gray" <Graya1@ukzn.ac.za>
February 15, 2006
• [e-drug] Abbott censored by ABPI for lapdancing junket
  • From: "E-Drug" <e-drug@healthnet.org>
• [e-drug] Complying with formularies improves patient adherence
  • From: "Andy Gray" <graya1@ukzn.ac.za>
• [e-drug] Exanta withdrawn after liver damage to patient
  • From: "E-Drug" <e-drug@healthnet.org>
• [e-drug] RFI: JuneLab PsoriaClear and Eczemate? (2)
  • From: "Kirsten Myhr" <myhr@online.no>
February 14, 2006
• [e-drug] RFI: JuneLab PsoriaClear and Eczemate?
  • From: "Drug Information " <druginformation@moh.gov.sc>
• [e-drug] Canada CL request for export of generic oseltamivir
  • From: "James Love" <james.love@cptech.org>
• [e-drug] Disease-mongering (2)
  • From: "jbapna" <jbapna@iihmr.org>
• [e-drug] Drugs executive to head Gates Foundation fund
  • From: "E-Drug" <e-drug@healthnet.org>
February 13, 2006
• [e-drug] Conference on Disease-mongering, Newcastle, 11-13 April
  • From: "David Henry" <david.henry@newcastle.edu.au>
• [e-drug] Drug promotion in developing countries (4)
  • From: "Nadeem Irfan Bukhari" <nadeemirfan_bukhari@imu.edu.my>
February 12, 2006
• [e-drug] New Goodman and Gilman
  • From: "Beverley Snell" <bev@burnet.edu.au>
• [e-drug] Breaches of Drug Promotion Code
  • From: "Beverley Snell" <bev@burnet.edu.au>
• [e-drug] Looking for drug and therapeutic commitee training (2)
  • From: "Atieno Ojoo" <atisojoo@yahoo.co.uk>
• [e-drug] Drug promotion in developing countries (3)
  • From: "Atieno Ojoo" <atisojoo@yahoo.co.uk>
• [e-drug] How to deal with H5N1 avian influenza outbreaks?
  • From: "E-drug" <e-drug@healthnet.org>
February 11, 2006
• [e-drug] Drug promotion in developing countries (2)
  • From: "Rollo Manning" <rollom@iinet.net.au>
• [e-drug] Community PRDU course, Nagpur, India, 1-8 March 2006
  • From: "Dr Vijay Thawani" <vijaythawani@blogspot.com>
• [e-drug] Drug promotion in developing countries
  • From: "Peter Mansfield" <peter.mansfield@adelaide.edu.au>
February 10, 2006
• [e-drug] India Patent Mailbox?
  • From: "Amy Nunn" <anunn@hsph.harvard.edu>
• [e-drug] ARV Drug Supply Management Training
  • From: "Melinda Wannenburg" <Melinda@aa4a.co.za>
• [e-drug] Looking for drug and therapeutic commitee training
  • From: "ribka mekonnen" <ribkamg@yahoo.com>
February 09, 2006
• [e-drug] International Conference of Drug Regulatory Authorities (3)
  • From: "Leo Offerhaus" <offerhausl@euronet.nl>
• [e-drug] Slow ARV roll-out 'killing [South] African children'
  • From: "E-Drug" <e-drug@healthnet.org>
• [e-drug] Regulatory Affairs Conference
  • From: "JPS Kohli" <info@businesshorizons.com>
• [e-drug] International Conference of Drug Regulatory Authorities (2)
  • From: "Rakesh Chaurasia" <rakeshchaurasia@macleodspharma.com>
February 08, 2006
• [e-drug] International Conference of Drug Regulatory Authorities
  • From: "Albert Figueras" <albert.figueras@gmail.com>
• [e-drug] DNDi: Greater EU Leadership Needed for R&D on Neglected Diseases
  • From: "Ann-Marie Sevcsik" <amsevcsik@dndi.org>
• [e-drug] MSF on tenofovir: false promises by Gilead?
  • From: "Sheila Shettle" <sheila.shettle@geneva.msf.org>
February 07, 2006
• [e-drug] Leishmaniasis (Kala-Azar) treatment (2)
  • From: "Margriet Den Boer" <margriet.den.boer@amsterdam.msf.org>
• [e-drug] WHO's 3x5 Has Garnered Momentum For Universal Antiretroviral Access
  • From: "E-Drug" <e-drug@healthnet.org>
• [e-drug] Leishmaniasis (Kala-Azar) treatment
  • From: "Mian Imran Masood" <drimranmasood@gmail.com>
February 06, 2006
• [e-drug] RFI: Chikungunya? (4)
  • From: "Mr. Kentish" <kent15@intnet.mu>
• [e-drug] RFI: Chikungunya? (3)
  • From: "Ruth Hope" <ruth.hope@verizon.net>
• [e-drug] Orphan drugs of Pakistan
  • From: "Huma Rasheed" <huma_rasheed@hotmail.com>
• [e-drug] Continuing education for pharmacists
  • From: "Sosola" <sosola@malawi.net>
February 05, 2006
• [e-drug] RFI: Chikungunya? (2)
  • From: "Mr. Kentish" <kent15@intnet.mu>
• [e-drug] RFI: paediatric use of injectable clarithromycin? (2)
  • From: "Kirsten Myhr" <myhr@online.no>
February 04, 2006
• [e-drug] Quality - an access related issue (2)
  • From: "Nadeem Irfan Bukhari" <nadeemirfan_bukhari@imu.edu.my>
• [e-drug] NYT: Rotavirus Vaccine Approved in USA
  • From: "Libby Levison" <libby@theplateau.com>
• [e-drug] RFI: paediatric use of injectable clarithromycin?
  • From: "Huma Rasheed" <huma_rasheed@hotmail.com>
• [e-drug] Quality - an access related issue
  • From: "Huma Rasheed" <huma_rasheed@hotmail.com>
• [e-drug] Influence prescribing by paying bonus (2)
  • From: "Dr. J.W.F. van Mil" <jwfvmil@planet.nl>
February 03, 2006
• [e-drug] New Canadian report on DTCA
  • From: "Joel Lexchin" <joel.lexchin@utoronto.ca>
• [e-drug] NYT: After Dreary '05, Drug Makers See Brighter Year Ahead
  • From: "Wilbert Bannenberg" <wjb@wxs.nl>
• [e-drug] Vacancy: MSF EU Liaison Officer Brussels
  • From: "Wilbert Bannenberg" <wjb@wxs.nl>
• [e-drug] Corruption in the pharmaceutical sector
  • From: "Wilbert Bannenberg" <wjb@wxs.nl>
• [e-drug] Vacancy: MMV chief access and delivery officer
  • From: "Wilbert Bannenberg" <wjb@wxs.nl>
• [e-drug] Influence prescribing by paying bonus
  • From: "Hilbrand Haak" <haakh@chd-consultants.nl>
February 02, 2006
• [e-drug] RFI: Chikungunya?
  • From: "sarita boolell" <sarita_ph@yahoo.com>
February 01, 2006
• [e-drug] WHO's 3X5 Garnered Momentum For Universal ARV Access
  • From: "Leela McCullough" <leela@healthnet.org>
• [e-drug] U.S. IPR Proposals for US-Thai FTA Worse than Feared
  • From: B.Baker@neu.edu
• [e-drug] Course: Managing Drug Supply in Developing Countries
  • From: "Jean-François Saint-Sauveur" <fsaintsauveur@idasolutions.org>
• [e-drug] Myths and Realities: U.S.-Thai FTA impact
  • From: B.Baker@neu.edu